Cancer Advisor

Executive Summary For over 70 years, the global standard for cancer prognosis has been the American Joint Committee on Cancer (AJCC) TNM staging system , which classifies tumors based on: T – Tumor size and local invasion N – Lymph node involvement M – Distant metastasis TNM staging remains foundational in oncology. It guides treatment selection, clinical trial design, and survival prediction. Yet clinicians and patients alike encounter a persistent paradox: Two patients. Same cancer. Same stage. Same treatment. Radically different outcomes. A growing body of research suggests that host metabolic status — particularly insulin resistance and hyperinsulinemia — may independently influence cancer progression, recurrence, and survival. This raises a provocative but clinically relevant question: Could metabolic markers such as insulin resistance provide prognostic insight that complements — or in some contexts rivals — anatomical staging? Staging explains part of the st...

The metabolic processes that help your body use food for energy and nourishment are extremely complex. The hormone insulin is a key player. When you eat, sugars from the food enter your bloodstream, which triggers your pancreas to release insulin. That insulin helps the sugar get into your cells to be used for energy. The insulin then ushers any extra sugar to your liver to be stored for later. Insulin also helps your body break down and use lipids, or fats. The amount of insulin in your body goes up and down according to how much sugar is in your bloodstream. But several factors can make your cells resistant to insulin. As a result, your blood sugar and insulin levels will be chronically elevated. Why Obesity and Insulin Resistance Reduce Immunotherapy Effectiveness Short answer: because immunotherapy depends on a metabolically fit immune system — and obesity and insulin resistance reprogram immunity in ways that blunt anti‑tumor response. This article explains how metabolic ...

GLP-1 receptor agonists such as Semaglutide and Tirzepatide have transformed the treatment of obesity and type 2 diabetes. As their use expands globally, a critical question is emerging: Do GLP-1 drugs reduce cancer risk — or is any apparent benefit simply a consequence of weight loss and improved metabolic health? This article reviews: The established link between obesity and cancer The biological mechanisms affected by GLP-1 therapy Human clinical trial data Observational cancer incidence studies Safety signals (including thyroid cancer) What remains unknown All claims below are supported by peer-reviewed sources. 1. Obesity and Cancer: Established Evidence The link between obesity and cancer is well established. The International Agency for Research on Cancer concluded in 2016 that excess body fat increases the risk of at least 13 cancers (1). Key cancers linked to obesity include: Colorectal Postmenopausal breast Endometrial Pancreatic Liver Mechanisms supported by human and transl...

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest human malignancies, with a five-year survival rate stubbornly below 15% despite decades of advances in surgery, chemotherapy, and molecular oncology. Most discussions focus on late diagnosis, aggressive genetics, or therapeutic resistance. Far less attention is paid to a quieter but increasingly evident factor: insulin resistance and metabolic dysfunction . Emerging evidence suggests that pancreatic cancer is not merely influenced by metabolic disease—it may be deeply intertwined with it . Insulin resistance often precedes diagnosis, worsens prognosis, and biologically fuels tumor growth. Yet it remains largely absent from staging systems, risk stratification, and treatment frameworks. A 2023 study from researchers at University of British Columbia’s Faculty of Medicine reveals a direct link between high insulin levels, common among patients with obesity and type 2 diabetes, and pancreatic cancer. The study, published...

In the search for innovative cancer treatments, oncology has traditionally focused on genetics—mutated DNA being the primary culprit driving tumor growth. However, a parallel revolution is taking place in the field of metabolic oncology . Instead of asking only what a cancer cell is genetically, researchers are asking: What does a cancer cell eat, and how does it breathe? At the very center of this metabolic paradigm shift sits the powerful axis of glucose, insulin, and insulin-like growth factors (IGFs) . Far from being a simple matter of "sugar feeds cancer," the biological reality of how hyperinsulinemia and glycemic variability drive malignancy is a complex, actionable frontier in modern medicine. 1. The Fuel and the Ignition: Glucose vs. Insulin To understand how this axis drives cancer progression, we must separate the raw fuel from the hormonal signal that ignites it. [ High Sugar Intake ] ──> [ Chronic Blood Glucose Spikes ]     ...

Cancer treatment is increasingly moving beyond the idea that tumors are driven only by genetic mutations. A growing body of research now suggests that metabolism — including glucose levels, insulin signaling, mitochondrial function, fatty liver disease, and ketone metabolism — may strongly influence how cancers grow, spread, and respond to treatment. One of the clearest examples of this connection is now emerging in liver cancer , where metabolic disease has become one of the fastest-growing causes worldwide. Researchers are beginning to explore whether improving metabolic health could potentially influence: cancer risk, tumor progression, inflammation, and even responses to immunotherapy. The Global Rise of Metabolic Disease Modern metabolic disease includes: obesity insulin resistance type 2 diabetes metabolic syndrome fatty liver disease These conditions are now increasingly linked to cancer development. Particularly: liver cancer colorectal cancer pancreatic cancer breast cancer en...

Cancer is not just a genetic disease. It is also deeply influenced by metabolism, inflammation, immunity, hormones, blood vessel growth, and the tumor microenvironment. One of the most fascinating concepts in modern oncology is that tumors require a constant supply of nutrients and oxygen in order to grow. Without access to blood vessels and metabolic fuel, many tumors struggle to expand. This idea helped popularize the phrase: “Starving cancer cells.” But what does that actually mean scientifically? The answer lies in understanding: Tumor angiogenesis (blood vessel growth) Cancer metabolism Chronic inflammation Insulin and glucose signaling Immune system regulation Nutrient-sensing pathways Dietary considerations for a cancer patient can be viewed as catering to two mouths: one of the patient, governed by personal choices and the body’s metabolic responses to feeding or fasting; and the other of the tumor, which imposes its own demands.  A 2025 review in Nature  examines diet...